Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie

Warsaw 02-097

0 studies enrolling now · 7 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Muscular Atrophy, Spinal, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), Relapsing Multiple Sclerosis, Spinal Muscular Atrophy, Spinal Muscular Atrophy (SMA)

Studies at this site

• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy — Running, not enrolling
• A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants — Completed